At BTG we are focused on bringing to market innovative products in specialist areas of medicine to better serve doctors and patients. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumours, advanced emphysema, severe blood clots, and varicose veins, while our Specialty Pharmaceuticals portfolio offers antidotes that alleviate toxicity and treat rare conditions. Healthcare is constantly evolving – so BTG never stands still. Inspired by a deep understanding of our customers’ needs, we’re working to meaningfully improve the lives of patients and their healthcare experience. Our competitive advantage is our dedication to finding smart, often unconventional solutions to complex medical problems. Many of our products combine medicines, device technology and new techniques in order to deliver more targeted treatments. We also invest in the clinical evidence that helps demonstrate the value of our products to doctors, patients, and healthcare systems. Doing what’s right for patients is what gets us to work in the morning. It’s part of our DNA. By staying true to this principle and our values, we’ve earned a strong reputation for the quality of our products and our commitment to innovation. Whether developed in our own labs or in partnership with clinicians, academics, and other companies, we believe passionately that medical innovation has the power to improve human health. Imagine where we can go.
London, GB
986 (est)

BTG Locations

London, GB
Alzenau, DE
Conshohocken, US
Brentwood, US
Ottawa, CA
Rosedale, AU
Neihu District, TW

BTG Metrics

BTG Summary

Founding Date


Market capitalization

£2.6 B

Closing share price


BTG Financials

FY, 2014FY, 2015FY, 2016


£291 M£368 M£448 M

Revenue growth, %


Gross profit

£196 M£253 M£307 M

Gross profit Margin, %


Operating expense total

£168 M£218 M£250 M

BTG Market Value History

BTG News

BTG Company Life